Utility of ROTEM in measuring hypercoagulability in COVID-19 patients. [COVID-19]
Research type
Research Study
Full title
Exploratory pilot study to evaluate utility of rotational thromboelastometry in identifying and tracking hypercoagulability in COVID-19 patients.
IRAS ID
284755
Contact name
Sophia Stanford
Contact email
Sponsor organisation
Hampshire Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 6 months, 17 days
Research summary
Patients with COVID-19 are known to have abnormal blood clotting which is seen particularly in more serious disease and is associated with a worse outcome. But we do not know how to use the various measures of blood clotting to give more individually tailored treatment or whether these measures can help predict those patients who are particularly at risk of major blood clots. \n\nThere are a number of routine tests but they are of limited value in COVID-19 because they only measure certain aspects of the clotting process in the body. There is a whole blood test that overcomes this called ‘rotational thromboelastometry’ or ‘ROTEM’. It can measure many more aspects of clotting in whole blood sample, not just the plasma. It can be done ‘at the bedside’ and takes only 10 minutes to provide the results. \n\nThis study will use what ROTEM can measure to make an assessment of blood clotting (including what is called the Maximum Clot Firmness or MCF) to see if it is different in patients with more serious disease. This will help us understand how the abnormal blood clotting caused by COVID-19 can be treated more successfully.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
20/SW/0101
Date of REC Opinion
5 Aug 2020
REC opinion
Further Information Favourable Opinion